EGI
ITCI

EAM Global Investors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

EAM Global Investors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,401
Closed -$3.61M – 130
2023
Q4 		$3.61M Buy
+50,401
New +$2.9M 0.87% 74
2022
Q3 		– Sell
-37,763
Closed -$2.16M – 258
2022
Q2 		$2.16M Sell
37,763
-12,055
-24% -$684K 0.53% 72
2022
Q1 		$3.05M Buy
49,818
+50
+0.1% +$2.6K 0.56% 44
2021
Q4 		$2.6M Buy
+49,768
New +$2.09M 0.46% 92

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM Global Investors's ITCI Position: Q1 2024 in Review

EAM Global Investors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 50,401 shares — an estimated $3.61M sold.

EAM Global Investors first reported a position in ITCI in Q4 2021 and held it in 4 quarters. The position peaked at $3.61M in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • EAM Global Investors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • EAM Global Investors sold 50,401 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $3.61M.
  • EAM Global Investors first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 4 quarters.
  • EAM Global Investors's Intra-Cellular Therapies Inc. position peaked at $3.61M in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on EAM Global Investors's 13F filing for Q1 2024, filed 13 May 2024.